Drug Search Results
More Filters [+]

Aftobetin

Alternative Names: aftobetin
Latest Update: 2018-08-22
Latest Update Note: Clinical Trial Update

Product Description

Aftobetin, also known as ANCA11 and NCE-11, is a novel amyloid–binding compound applied topically in the form of an ophthalmic ointment. Aftobetin offers a promising way for a noninvasive eye-scan to diagnose Alzheimer’s disease early. (Sourced from: https://drugs.ncats.io/substance/9GY611K4TC)

Mechanisms of Action: AB Degrader

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cognoptix
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aftobetin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Alzheimer Disease|Cognitive Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRT-0036

P1

Unknown status

Alzheimer Disease|Cognitive Dysfunction

2018-12-01

Recent News Events

Date

Type

Title